On April 21, 2025, Hindustan Unilever Limited (HUL) officially announced the completion of its acquisition of Uprising Science Private Limited. Following approval from the Competition Commission of India, the deal cements Uprising’s status as a subsidiary of HUL through a significant financial transaction.
Hindustan Unilever Limited had previously disclosed, through its communication dated 18th March 2025, that regulatory approval had been granted by the Competition Commission of India for the proposed acquisition. The transaction was carried out in accordance with the Share Purchase and Subscription Agreement (SPSA) signed on 22nd January 2025. Under the terms of the agreement, HUL successfully acquired a 90.5% stake in Uprising Science Private Limited. This acquisition was completed through a combination of primary infusion and secondary purchase, amounting to a total cash consideration of ₹2,706.44 crore.
As a result of this acquisition, Uprising Science Private Limited and its subsidiaries have officially become subsidiaries of Hindustan Unilever Limited. This move aligns with HUL’s broader strategic initiatives and marks a significant expansion of its operational base. The acquisition not only strengthens HUL’s market position but also integrates Uprising’s resources and capabilities into its corporate structure, enhancing overall business synergies.
Read More: HUL, RIL Lead as Top Indian Firms Add ₹84,559 Cr in Market Capitalisation
As of April 22, 2025, 10:30 AM, HUL Share Price is trading at ₹2,382.80, reflecting a 1.35% surge from the previous closing price. Over the past month, the stock has surged by 5.61%.
The acquisition of a 90.5% stake in Uprising Science Private Limited marks a major milestone for Hindustan Unilever Limited. Through this transaction, HUL has expanded its corporate portfolio and reinforced its commitment to growth and innovation within the Indian market.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Apr 22, 2025, 2:29 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates